Douglas D Burkett Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Douglas Burkett CSBR stock SEC Form 4 insiders trading

Douglas has made over 3 trades of the Champions Oncology Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Douglas bought 1,000 units of CSBR stock worth 850$ on 3 October 2008.

The largest trade Douglas's ever made was buying 1,500 units of Champions Oncology Inc stock on 30 September 2008 worth over 1,500$. On average, Douglas trades about 1,333 units every 3 days since 2008.

You can see the complete history of Douglas Burkett stock trades at the bottom of the page.

What's Douglas Burkett's mailing address?

Douglas's mailing address filed with the SEC is 1820 EAST RAY ROAD, , CHANDLER, AZ, 85225.

Insiders trading at Champions Oncology Inc

Over the last 21 years, insiders at Champions Oncology Inc have traded over 9,072,751$ worth of Champions Oncology Inc stock and bought 42,104,566 units worth 13,657,266$ . The most active insiders traders include Ventures Ix, L.P.Battery In...、Michael Maurice Brown、Sports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of 2,196,294$. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth 6,500$.

What does Champions Oncology Inc do?

champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them

Complete history of Douglas Burkett stock trades at Champions Oncology Inc

Champions Oncology Inc executives and stock owners

Champions Oncology Inc executives and other stock owners filed with the SEC include:

• Ronnie Morris,
  Chief Executive Officer, Director
• Dr. Ronnie Morris M.D.,
  Pres, CEO & Director
• David Miller,
  Chief Financial Officer
• David Barry Miller M.B.A.,
  Chief Financial Officer
• Joel Ackerman,
  Chairman of the Board
• Scott Tobin,
  Independent Director
• Abba Poliakoff,
  Independent Director
• Daniel Mendelson,
  Independent Director
• David Sidransky,
  Lead Independent Director
• Philip Breitfeld,
  Independent Director
• David DeOrnellis BS, CMAR, CPIA, RLATG,
  Exec. VP of Global Laboratory Operations
• Dr. Maria Mancini Ph.D.,
  Chief of Scientific Operations
• Dr. Michael Ritchie M.B.A., Ph.D.,
  Chief Commercial Officer
• Dr. Karin Abarca Heidemann,
  VP of Scientific Operations
• Ventures Ix, L.P.Battery In...,
  
• Michael Maurice Feldman Jes...,
  
• Ventures Ix, L.P.Battery In...,
  
• Arthur G Iii Epker,
  Director
• Michael Maurice Brown,
  10% owner
• James Martell,
  Chief Accounting Officer
• Ana Stancic,
  Director
• Douglas D Burkett,
  President
• Mark Schonau,
  Chief Financial Officer
• Durwood Settles,
  Director
• Sports Inc Champions,
  Chairman, President
• Enterprise Associates 14, L...,
  
• Brady Davis,
  President